In the past years, PPARα agonists have been proposed for repurposing as potential agents for the treatment of neuropsychiatric disorders [27,49,122] and neurodegenerative diseases [28], in consideration of their role in the regulation of gene expression in pathways that control oxidative stress and neuroinflammatory responses. This evidence concerns the gene PPARA and neurodegenerative disease.